47 108

Cited 0 times in

Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author성진실-
dc.contributor.author안상훈-
dc.contributor.author원종윤-
dc.contributor.author이혜원-
dc.contributor.author한광협-
dc.contributor.author한대훈-
dc.contributor.author한소정-
dc.date.accessioned2021-01-19T08:06:04Z-
dc.date.available2021-01-19T08:06:04Z-
dc.date.issued2020-12-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181465-
dc.description.abstractBackgrounds and aims: Molecular-targeted agents are acceptable standards to treat advanced-stage hepatocellular carcinoma (HCC), however, their therapeutic benefit, ie, sorafenib, was significantly offset in case of major vessel invasion. Liver-directed concurrent chemo-radiotherapy (LD-CCRT) provided favorable outcomes in terms of survivals and tumor shrinkage, so, we appraised its long-term therapeutic efficacy. Patients and methods: Advanced HCC patients with portal vein invasion (main trunk or the 1st order branch) were enrolled. During a 5-week radiotherapy course, concurrent hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and leucovorin was administered through an implanted port on the first and last 5 days. Four weeks after LD-CCRT, a maintenance HAIC using 5-fluorouracil and cisplatin was administered every 4 weeks. Results: Among 152 patients, the objective response rates as the best response by modified Response Evaluation Criteria In Solid Tumors were 48.0% after LD-CCRT and 55.3% during subsequent HAIC maintenance. After LD-CCRT, biological responses in alpha-fetoprotein and protein induced by the absence of vitamin K or antagonist-II levels were achieved in 46.2% and 52.6%, respectively. Sixteen patients (10.5%) underwent curative resection or liver transplantation after down-staging. Median overall survival and progression-free survival were 13.5 and 6.9 months, respectively. Conclusion: LD-CCRT followed by maintenance HAIC yielded favorable survival outcomes in advanced HCC patients with major portal vein invasion. Through initial tumor reduction, LD-CCRT induced down-staging with subsequent curative treatment feasible in 10.5% of patients, resulting in long-term survival. Further prospective trials are warranted to confirm these results.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherDove Press-
dc.relation.isPartOfJOURNAL OF HEPATOCELLULAR CARCINOMA-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAppraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSojung Han-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorJinsil Seong-
dc.contributor.googleauthorJong Yun Won-
dc.contributor.googleauthorDai Hoon Han-
dc.contributor.googleauthorBeom Kyung Kim-
dc.identifier.doi10.2147/JHC.S276528-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA01675-
dc.contributor.localIdA01956-
dc.contributor.localIdA01956-
dc.contributor.localIdA02226-
dc.contributor.localIdA02226-
dc.contributor.localIdA02443-
dc.contributor.localIdA02443-
dc.contributor.localIdA03318-
dc.contributor.localIdA03318-
dc.contributor.localIdA04268-
dc.contributor.localIdA04268-
dc.contributor.localIdA04273-
dc.contributor.localIdA04273-
dc.contributor.localIdA05438-
dc.contributor.localIdA05438-
dc.relation.journalcodeJ03970-
dc.identifier.eissn2253-5969-
dc.identifier.pmid33365287-
dc.subject.keywordconcurrent chemoradiotherapy-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordportal vein invasion-
dc.subject.keywordprognosis-
dc.subject.keywordresponse-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor원종윤-
dc.contributor.affiliatedAuthor원종윤-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한광협-
dc.contributor.affiliatedAuthor한대훈-
dc.contributor.affiliatedAuthor한대훈-
dc.contributor.affiliatedAuthor한소정-
dc.contributor.affiliatedAuthor한소정-
dc.citation.volume7-
dc.citation.startPage403-
dc.citation.endPage412-
dc.identifier.bibliographicCitationJOURNAL OF HEPATOCELLULAR CARCINOMA, Vol.7 : 403-412, 2020-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.